, a novel species discovered in Japan in 2023, has not been reported to infect humans. Here, we report a case of pulmonary nocardiosis in a 70-year-old immunocompetent woman infected with . The patient presented to the hospital with a chief complaint of weight loss. She worked at a fruit sorting facility where she was exposed to dust. Chest computed tomography revealed a single cavity and diffuse nodular opacities in both lungs. species was isolated from tracheal sputum and bronchial lavage fluid and identified as via 16S rRNA gene sequencing. The patient was treated with oral sulfamethoxazole and trimethoprim but developed oral mucositis on the 12th day of treatment. Consequently, minocycline was prescribed, and the patient's condition improved after a six-month course of treatment. To our knowledge, this is the first reported case of pulmonary nocardiosis caused by in humans. Accurate species identification and antimicrobial susceptibility tests will be necessary to prescribe appropriate treatment for infections.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371458 | PMC |
http://dx.doi.org/10.7759/cureus.66137 | DOI Listing |
Respir Med
December 2024
Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan. Electronic address:
Background: Pulmonary nocardiosis is a rare opportunistic infection, with approximately 15 % of patients being immunocompetent. The isolation rate of Nocardia spp. has recently increased, indicating rising clinical concern.
View Article and Find Full Text PDFFront Cell Infect Microbiol
December 2024
Key Laboratory of Efficient Utilization of Non-grain Feed Resources (Co-construction by Ministry and Province) of Ministry of Agriculture and Rural Affairs, Shandong Agricultural University, Taian, Shandong, China.
The northern snakehead () is a valuable aquaculture species across certain Asian countries, contributing significantly to economic prosperity and dietary needs. However, its productivity faces significant challenges, particularly from diseases such as nocardiosis, caused by . To date, the majority of research efforts have focused on describing the observed phenomena related to infection.
View Article and Find Full Text PDFFront Microbiol
December 2024
Department of Research and Development, Satras Biotechnology Company, Islamic Azad University of Khomein, Khomein, Iran.
Introduction: Microbial contamination in food products such as pastries, poses a significant public health concern due to the potential risks of foodborne infection and outbreak, Therefore, to prevent these infections, it is essential to investigate the frequency and extent of microbial contamination as well as the level of drug resistance in pastries. Due to this issue, our study aimed to assess the microbial diversity and the drug susceptibility patterns of microbial pollutants in pastry shops in Markazi province, Iran.
Methods: The study involved collecting 120 pastry samples from 30 pastry shops in Markazi province, Iran.
Ann Clin Microbiol Antimicrob
December 2024
Laboratoire de Biologie médicale de Référence des Nocardioses, Groupement Hospitalier Nord, Institut des Agents Infectieux, Hospices civils de Lyon, Lyon, France.
Background: Drug susceptibility testing (DST) for Nocardia spp. is essential to initiate effective antibiotic therapy. Currently, the only recommended technique is the determination of minimum inhibitory concentrations (MICs) by microdilution.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation, 191036 Saint-Petersburg, Russia.
Infections caused by nontuberculous mycobacteria (NTM) are rising globally throughout the world. The number of species isolated from clinical samples is steadily growing, which demands the implementation of a robust diagnostic method with wide specificity. This study was carried out in in 2022-2024 in three clinical antituberculosis centers in the biggest cities of Russia: Moscow, Saint Petersburg, and Novosibirsk.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!